Supplementary Files
Keywords
Extracted dialyzable leukocytes
Transfer factors
Immunomodulatory
Immunotherapy
Abstract
Background: Dialyzable leukocyte extracts (DLE) have been used to treat several cellular immunodeficiency.
Objective: To review the experience of a tertiary hospital in the use of DLE for the treatment of recurrent or severe infections in children with acquired cellular immunodeficiency not due to HIV.
Methods: We reviewed the medical records of all children who received treatment with EDL of human or bovine origin between 1986 and 2000 to detect recurrent or severe infections without response to a specific antimicrobial therapy and with a quantitative or qualitative deficit in the cellular immune response. The dose of DLE was adjusted according to the percentage of T lymphocytes; the evolution of the patient was evaluated retrospectively for 5 years, the immune response was evaluated by subpopulation of lymphocytes and intradermal tests and inhibition of the leukocyte migration assay (LIF) to PPD, coccidioidin, varidase and candidin.
Results: 150 children received DLE, age 7.0 ± 5.9 years. The most frequent indications included upper respiratory tract (71%), lower respiratory tract (43%), gastrointestinal tract (15%), urinary tract (15%) and neurological infections (4%) and coccidioidomycosis (3%). After starting the DLE, the numbers of T lymphocytes, LIF to PPD and varidase (> 20%) and the intradermal induration of the test increased (p <0.001). In 6 patients (4%) recurrences of respiratory and gastrointestinal tract infections were observed, which resolved, no adverse effects attributable to the DLE were reported.
Conclusions: The use of DLE for recurrent or severe infectious processes in children with cellular immune deficit improved the clinical evolution and the immunological parameters evaluated without adverse effects attributable to their use.
References
Lawrence HS. The cellular transfer of cutaneous hypersensitivity to tuberculin in man. Proc Soc Exp Biol Med. 1949;71(4):516-522. DOI: 10.3181/00379727-71-17242
Salazar-Villa RM, Mejía-Ortega J. Uso del factor de transferencia en el asma bronquial alérgica. Rev Alerg Mex. 1993;40(2):42-45.
Valdés-Sánchez AF, Fernández-Ortega C, Gómez-Echeverría AH, Gillama-Niebla E, Lastra-Alfonso G, López-Saura PA. Dermatitis atópica. Tratamiento con factor de transferencia. Ensayo clínico controlado. Rev Alerg Mex. 1991;38(6):158-162.
Abramson A, Khan A, Tate GW, Martin RG, Hill NO. Immunocompetence and transfer factor therapy in uveitis. Br J Opthalmol. 1980;64(5):332-338. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1043690/
Dwyer JM. Transfer factor in the age of molecular biology: a review. Biotherapy. 1996;9(1-3):7-11. DOI: 10.1007/BF02628650
Lawrence HS, Borkowsky W. Transfer factor: current status and future prospects. Biotherapy. 1996;9(1-3):1-5. DOI: 10.1007/BF02628649
Steele RW, Myers MG, Vincent MM. Transfer factor for the prevention of varicella-Zoster infection in childhood leukemia. New Engl J Med. 1980;303(7):335-339. DOI: 10.1056/NEJM198008143030702
Sánchez-González DJ, Sosa-Luna CA, Vásquez-Moctezuma I. Factores de transferencia en la terapéutica médica. Med Clin (Barcelona). 2011;137(6):273-277. DOI: 10.1016/j.medcli.2010.05.002
Cruz-Barrios MA, Rodríguez-Montiel BN, Furones-Mourrelle JA, Martín-De la Riva AD, Guerra-Suárez LM, Páez-Pérez AT. Patrones de prescripción del factor de transferencia en 11 hospitales de ciudad de la Habana, 2002. Rev Cubana Salud Pub. 2005;31(4):291-295. Disponible en: https://www.redalyc.org/articulo.oa?id=21418845004
Martínez-Torres AC, Reyes-Ruiz A, Benítez-Londoño M, Franco-Molina MA, Rodríguez-Padilla C. Immunepotent CRP induces cell cycle arrest and caspase-independent regulated cell death in HeLa cells through reactive oxygen species production. BMC Cancer. 2018;18(1):13. DOI 10.1186/s12885-017-3954-5
Wu HM, Tang JL, Cao L, Sha ZH, Li Y. Interventions for preventing infection in nephritic syndrome. Cochrane Database Syst Rev. 2012;(4):CD003964. DOI: 10.1002/14651858.CD003964.pub3
Gómez-Vera J, Chávez-Sánchez R, Flores-Sandoval G, et al. Factor de transferencia y alergia. Rev Alerg Mex. 2010;57:220-227.
Navarro-Cruz D, Serrano-Miranda E, Orea-Solano M, et al. Factor de transferencia en dermatitis atópica moderada y severa. Rev Alerg Mex. 1996;43(5):116-123.
Coronado-Cerda EE, Franco-Molina MA, Mendoza-Gamboa E, Prado-García H, Rivera-Morales LG, Zapata-Benavides P, et al. In vivo chemoprotective activity of bovine dialyzable leukocyte extract in mouse bone marrow cells against damage induced by 5-Fluorouracil. J Immunol Res. 2016;2016:6942321. DOI: 10.1155/2016/6942321
Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, Vera-García ME, Castillo-Tello P, García-De-La-Fuente A, et al. Immunepotent CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy. 2008;10(5):490-496. DOI: 10.1080/14653240802165681
Franco-Molina MA, Mendoza-Gamboa E, Miranda-Hernández DF, Sierra-Rivera CA, Zapata-Benavides P, Vera-García ME, et al. Anti-inflammatory and antioxidant effects of Immunepotent CRP in lipopolysaccharide (LPS)-stimulated human macrophages. Afr J Microbiol Res. 2011;5:3726-3736.
Rodríguez-Salazar MDC, Franco-Molina MA, Mendoza-Gamboa E, Martínez-Torres AC, Zapata-Benavides P, López-González JS, et al. The novel immunomodulator Immunepotent CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth. Oncol Lett. 2017;14(1):844-852. DOI: 10.3892/ol.2017.6202
Lawrence HS, Al-Askari S. The preparation and purification of transfer factor. En: Bloom BR, Glade PR (editors). In vitro methods in cell mediated immunity. EE. UU.: Academic Press; 1971.
Cavazos-Cavazos AM. Inmunoterapia con factor de transferencia en pacientes con coccidiodomicosis. [Tesis de maestría]. México: Universidad Autónoma de Nuevo León; 1989.
Hannet I, Erkeller-Yuksel F, Lydyard P, Deneys V, DeBruyère M. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today. 1992;13(6):215-218. DOI: 10.1016/0167-5699(92)90157-3
Shearer WT. Monitoring cellular immune function in HIV infection by the delayed hypersensitivity skin test: alternative to the CD4 T-cell count? J Allergy Clin Immunol. 1999;103(1 Pt 1):26-28. DOI: 10.1016/S0091-6749(99)70520-8
Kalish R, Askenasa P. Molecular mechanism of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma and autoimmunity. J Allergy Clin Immunol 1999:103:192-199.
Borkowsky W, Lawrence HS. Effects of human leukocyte dialyzable containing transfer factor in the direct leukocyte migration inhibition (LMI) assay. J Immunol. 1979;123(4):1741-1748.
Gerbase-DeLima M, Carlquist I, Mendes NF. Specificity of the local transfer of cell-mediated immunity with dialyzable transfer factor. Cell Immunol. 1979;48(1):231-234. DOI: 10.1016/0008-8749(79)90115-1
Kirkpatrick CH. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med. 2000;6(4):332-341. Disponible en: https://www.extratosalergenicos.com.br/Papers/imunotransferan/Transfer%20Factors%20Identification%20of%20Conserved%20Sequences.pdf
Hadden W. Immunopharmacology: immunomodulation and immunotherapy. JAMA. 1987;258(22):2008-2017. DOI: 10.1001/jama.1997.03550220214027
Estrada-Parra S, Chávez-Sánchez R, Ondarza-Aguilera R, Correa-Meza B, Serrano-Miranda E, Monges-Nicolau A, et al. Immunotherapy with transfer factor of recurrent herpes simplex type I. Arch Med Res. 1995;26:S87-S92.
Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, et al. Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses. Biotherapy. 1996;9(1-3):67-72.
Kirkpatrick CH, Hamond AR, Morton LC. Murine transfer factors: dose-response relationships and routes of administration. Cell Immunol. 1995;164(2):203-206. DOI: 10.1006/cimm.1995.1162
Cid-Chávez DM, Ruiz-Pedraza MD, Sánchez-Sánchez LM, Staines-Boone AT, Castro-Pineda J, Palacios-Saucedo GD. Características clínicas e inmunológicas en pacientes pediátricos con coccidioidomicosis en el noreste de México. Gac Med Mex. 2013;149:541-547. Disponible en: https://www.anmm.org.mx/GMM/2013/n5/GMM_149_2013_5_541-547.pdf
Kirkpatrick CH. Activities and characteristics of transfer factors. Biotherapy. 1996;9(1-3):13-16. DOI: 10.1007/BF02628651
Fudenberg HH. Dialysable lymphocyte extract (DLyE) in infantile onset autism: a pilot study. Biotherapy. 1996;9(1-3):143-147. DOI: 10.1007/BF02628672
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2019 Revista Alergia México